DK1240186T3 - Forbedringer i eller relateret til immunrespons mod HIV - Google Patents

Forbedringer i eller relateret til immunrespons mod HIV

Info

Publication number
DK1240186T3
DK1240186T3 DK00985690.7T DK00985690T DK1240186T3 DK 1240186 T3 DK1240186 T3 DK 1240186T3 DK 00985690 T DK00985690 T DK 00985690T DK 1240186 T3 DK1240186 T3 DK 1240186T3
Authority
DK
Denmark
Prior art keywords
hiv
immune response
immunogen
synthetic polypeptide
protein
Prior art date
Application number
DK00985690.7T
Other languages
English (en)
Inventor
Tomas Hanke
Andrew James Mcmichael
Original Assignee
Medical Res Council
Int Aids Vaccine Initiative
Univ Nairobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930294.5A external-priority patent/GB9930294D0/en
Priority claimed from GB0025234A external-priority patent/GB0025234D0/en
Application filed by Medical Res Council, Int Aids Vaccine Initiative, Univ Nairobi filed Critical Medical Res Council
Application granted granted Critical
Publication of DK1240186T3 publication Critical patent/DK1240186T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00985690.7T 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV DK1240186T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930294.5A GB9930294D0 (en) 1999-12-23 1999-12-23 Improvements in or relating to immune responses to HIV
GB0025234A GB0025234D0 (en) 2000-10-14 2000-10-14 Improvements in or relating to immune responses to HIV
PCT/GB2000/004984 WO2001047955A2 (en) 1999-12-23 2000-12-22 Improvements in or relating to immune responses to hiv

Publications (1)

Publication Number Publication Date
DK1240186T3 true DK1240186T3 (da) 2010-05-31

Family

ID=26245157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985690.7T DK1240186T3 (da) 1999-12-23 2000-12-22 Forbedringer i eller relateret til immunrespons mod HIV

Country Status (15)

Country Link
US (1) US7993651B2 (da)
EP (1) EP1240186B1 (da)
JP (1) JP4805511B2 (da)
CN (1) CN1213068C (da)
AT (1) ATE457996T1 (da)
AU (1) AU784679B2 (da)
BR (1) BR0016510A (da)
CA (1) CA2392877C (da)
CY (1) CY1110917T1 (da)
DE (1) DE60043856D1 (da)
DK (1) DK1240186T3 (da)
ES (1) ES2341429T3 (da)
MX (1) MXPA02006379A (da)
PT (1) PT1240186E (da)
WO (1) WO2001047955A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7425611B2 (en) * 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
AU2004276559A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGENIC AND ITS APPLICATIONS
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2243788A1 (en) * 2005-02-24 2010-10-27 Medical Research Council HIVCON: An HIV immunogen and uses thereof
AU2007256717B2 (en) * 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
WO2010096561A1 (en) * 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2638060A2 (en) * 2010-11-10 2013-09-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014040025A2 (en) 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015138698A1 (en) * 2014-03-12 2015-09-17 Temple University-Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
EP3426353A4 (en) 2016-03-09 2020-05-06 The University of Massachusetts USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Seattle Project Corp. HIV antigens and MHC complexes
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JP2869063B2 (ja) * 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5175098A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5175097A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5993819A (en) * 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
US5210181A (en) * 1989-05-15 1993-05-11 Akzo N.V. T-lymphotropic retrovirus peptide
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
US6225045B1 (en) * 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
CA2262432A1 (en) * 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
WO1998043669A1 (en) * 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6656471B1 (en) * 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1088889A1 (en) * 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage

Also Published As

Publication number Publication date
DE60043856D1 (de) 2010-04-01
JP2003518931A (ja) 2003-06-17
CA2392877A1 (en) 2001-07-05
PT1240186E (pt) 2010-03-25
CN1434831A (zh) 2003-08-06
AU2208901A (en) 2001-07-09
WO2001047955A3 (en) 2002-05-10
CN1213068C (zh) 2005-08-03
BR0016510A (pt) 2002-08-27
US7993651B2 (en) 2011-08-09
HK1058048A1 (en) 2004-04-30
JP4805511B2 (ja) 2011-11-02
WO2001047955A2 (en) 2001-07-05
AU784679B2 (en) 2006-05-25
CA2392877C (en) 2011-11-15
ES2341429T3 (es) 2010-06-21
EP1240186B1 (en) 2010-02-17
EP1240186A2 (en) 2002-09-18
MXPA02006379A (es) 2004-06-21
CY1110917T1 (el) 2015-06-10
ATE457996T1 (de) 2010-03-15
US20030108562A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
DE60043856D1 (de) Verbesserungen in oder in bezug auf immunantworten gegen hiv
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
EP0339504A3 (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
CN101969996A (zh) 多价疫苗
Natuk et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.
Fast et al. Human trials of experimental AIDS vaccines
EP1601328A2 (en) Polyvalent immunogen
CA2077651C (en) Peptides stimulating cytotoxic t cells immune to hiv rt
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Clerici et al. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
HK141594A (en) Peptide fragments of HIV and their use in vaccines and diagnosis
RU2002126396A (ru) Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
WO1998041536A9 (en) Glycosylation deficient siv and hiv envelope glycoproteins
Earl et al. Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques
Böttiger et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
DeVICO et al. Purification and partial characterization of human immunodeficiency virus type 2 reverse transcriptase
OA10271A (en) Multiple branch peptide constructions for use against hiv
DE69217614D1 (de) Hybride, lösliche und nicht gespaltene gp160-variante
Clutton et al. Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines
EP1625144A2 (en) Polyvalent immunogen
Pyle et al. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF
Nardelli et al. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant
Okuda et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection